Fueling the breast care continuum with our Genius AI solution

Genius AI illustration

Hologic Introduces Core Artificial Intelligence Technology


At Hologic, we are focused on providing best in class, reliable and efficient solutions across the breast health continuum—from screening to biopsy to surgery, pathology to oncology, and with analytics software to support these solutions. That’s why we are proud to introduce Genius AI™, our core artificial intelligence technology that builds on our 30-year track record in breast health. Genius AI™ technology will integrate across the breast care continuum to provide benefits in three key areas:

  • Cancer Detection
    With the application of Genius AI™ technology to Hologic’s screening products, radiologists can detect breast cancer earlier and with the highest confidence.

  • Operational Efficiency
    Hologic’s intimate understanding of customer workflow allows us to deliver AI solutions that help clinicians and administrators do their jobs better, faster, and more efficiently.

  • Clinical Decision Support
    Clinical tools based on Genius AI™ solutions provide insights to help direct the patient pathway and aid physicians in making the best decisions for every patient.

Innovation in breast health is part of our DNA. We revolutionized breast cancer screening with the introduction of the Genius™ 3D™ exam in 2009, which has become the gold standard in mammography and is the only exam proven to increase invasive cancer detection by 20-65% compared to 2D alone1. The Genius™ exam also reduces callbacks by up to 40%2,3*. Now, our Genius AI™ solution powers our next major innovation in the evolution of mammography: 3DQuorum™ imaging technology.

Based on advanced artificial intelligence algorithms, 3DQuorum™ technology provides the full diagnostic power of Hologic’s highest resolution tomosynthesis technology, while reducing the number of images for radiologists to review by two-thirds. In combination with workflow tools to increase radiologists’ and technologists’ productivity, 3DQuorum™ technology delivers on the promise of our Genius AI™ solution by improving patient outcomes and driving operational efficiency.

“Our Genius AI™ solution will power our leading portfolio of products across the breath health continuum,” said Samir Parikh, VP of R&D, Breast and Skeletal Health at Hologic. “With innovations like 3DQuorum™ technology and the application of new technologies such as deep learning to identify subtle cancers in images, our Genius AI™ solution will have a huge impact for our customers and the patients they serve.”

Developed with clinicians and their patients in mind, we relied on the insights of customers to guide our AI product roadmap. As we continue to innovate in this space, we look forward to continuing this partnership to deliver best in class products that complement the physician and provide the necessary tools and insights to deliver superior patient care.

*Compared to 2D alone
    1. Results from Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital mammography." JAMA 311.24 (2014): 2499-2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia® Dimensions® on screening outcomes. Individual results may vary. The study found an average 41% (95% CI: 20-65%) increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1000 screening exams were found in women receiving combined 2D FFDM and 3D™ mammograms acquired with the Hologic 3D Mammography™ System versus women receiving 2D FFDM mammograms only.
    2. Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014 Jun 25;311(24):2499-507.
    3. Bernardi D, Macaskill P, Pellegrini M, et. al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug;17(8):1105-13.